Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 5, Pages 624
Publisher
MDPI AG
Online
2019-05-13
DOI
10.3390/cancers11050624
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune Checkpoint Inhibitor-Induced Reinvigoration of Tumor-Infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma
- (2019) Junsik Park et al. CLINICAL CANCER RESEARCH
- Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma
- (2019) Shahrzad Jalali et al. Blood Cancer Journal
- WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
- (2019) Lorenzo Castagnoli et al. ONCOGENE
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery
- (2019) Åsa Kristina Öjlert et al. Molecular Oncology
- Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
- (2019) Roberto Ferrara et al. Journal of Thoracic Oncology
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells
- (2018) Wei Xiao et al. JOURNAL OF IMMUNOLOGY
- Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
- (2018) Genevieve P Hartley et al. Cancer Immunology Research
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Hyperprogressive disease: recognizing a novel pattern to improve patient management
- (2018) Stéphane Champiat et al. Nature Reviews Clinical Oncology
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy
- (2017) Julia K. Tietze et al. EXPERIMENTAL DERMATOLOGY
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Expression of checkpoint molecules on myeloid-derived suppressor cells
- (2017) Marlene Ballbach et al. IMMUNOLOGY LETTERS
- PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation
- (2017) Sheema Almozyan et al. INTERNATIONAL JOURNAL OF CANCER
- Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling
- (2017) Kai Yang et al. NATURE
- COX2/mPGES1/PGE2pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
- (2017) Victor Prima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- (2017) Janet Lau et al. Nature Communications
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab
- (2017) Gabriele Madonna et al. OncoImmunology
- PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
- (2017) Jan Willem Kleinovink et al. OncoImmunology
- Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
- (2016) Curtis A. Clark et al. CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
- (2016) Lucia Festino et al. DRUGS
- CD28 Costimulation: From Mechanism to Therapy
- (2016) Jonathan H. Esensten et al. IMMUNITY
- Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8 + T Cell Exhaustion
- (2016) Bertram Bengsch et al. IMMUNITY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
- (2016) Chunwan Lu et al. OncoImmunology
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
- (2015) Nikolaos Patsoukis et al. Nature Communications
- Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
- (2015) Jon Bjoern et al. OncoImmunology
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3
- (2013) Aleksandra Kowalczyk et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood
- (2012) Peter T Sage et al. NATURE IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs
- (2010) Yenkel Grinberg-Bleyer et al. JOURNAL OF CLINICAL INVESTIGATION
- Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
- (2010) N. Jain et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Molecular mechanism and function of CD40/CD40L engagement in the immune system
- (2009) Raul Elgueta et al. IMMUNOLOGICAL REVIEWS
- CD4+regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
- (2009) Randall H. Friedline et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CD4+CD25+ Regulatory T Cells Suppress Mast Cell Degranulation and Allergic Responses through OX40-OX40L Interaction
- (2008) Giorgia Gri et al. IMMUNITY
- Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation
- (2008) Thomas Lehner IMMUNOLOGY
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search